Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MeDiSyn

Financiado

Scalable Microbial Metabolite Discovery Through Synthetic Biology

The discoveries of microbial secondary metabolites (SM) led to an incalculable impact on human health and lifespan. A large share of the antibiotics, anticancers and immunosuppressants in use today originate from microorganisms. H... ver más

31/12/2028

INSERM

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-14

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

INSERM

1.49M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2015-125 MINICELL 200K€ Cerrado

BIO2017-82462-R IDENTIFICACION Y CARACTERIZACION DE AGRUPAMIENTOS DE GENES B... 218K€ Cerrado

CyanoAsterisMETAB Exploration of the biosynthetic potential of the secondary m... 174K€ Cerrado

RYC2020-028880-I Computational and synthetic biology 324K€ Cerrado

crInSitu In situ genetic perturbation of gut bacteria with engineered... 2M€ Cerrado

EIN2019-103328 PROGRAMABLE LIVING DRUGS ENGINEERING MICROBIAL CELLS 25K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2023-11-14
Fecha Fin: 2028-12-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto The discoveries of microbial secondary metabolites (SM) led to an incalculable impact on human health and lifespan. A large share of the antibiotics, anticancers and immunosuppressants in use today originate from microorganisms. However, discoveries of SMs of microbial origin through traditional approaches have declined in the past decades, depriving drug pipelines from a key source of bioactive molecules. The consequences are dire, in particular in the case of antibiotics. Encouragingly, the study of the biosynthetic genes responsible for the synthesis of SMs indicates that the natural repertoire remains vastly underexplored, and new ways to access it are enabled by DNA technologies. In particular, untapped biosynthetic genes can be interrogated by transferring them into heterologous hosts. I am developing a method for transfer which fulfils the conditions to unleash theoretically massive economies of scale. Here I propose to multiply the scalability of the current heterologous expression framework and effectively overcome the diminishing returns faced by traditional approaches. In the first axis, I will implement a full-fledged discovery platform, optimized to systematically interrogate novel biosynthetic gene clusters identified bioinformatically from a large collection of soil bacteria. Second, the scale and parallel nature of the heterologous expression setup will be used to better understand the logic of activation of biosynthetic genes, and identify optimal ways to increase activation rates among the large reservoir of conditionally silent biosynthetic genes. Finally, the general strategy will be extended to new fungal and bacterial clades to enable interrogation of their vast potential through scalable heterologous expression. Overall, this proposal aims at developing heterologous expression into a major way to discover microbial secondary metabolites and drug leads.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores